UNSPSC 51282410: Temocillin

This classification denotes a penicillin antibiotic with the molecular formula C16H18N2O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 03QB156W6I, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((carboxy-3-thienylacetyl)amino)-6-methoxy-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6alpha))- but generally known as temocillin, which bears US NIH Compound Identifier 171758.

UNSPSC 51282410 Temocillin (Commodity) shows minimal relevant recent state and local procurement activity. The code nominally covers a specific beta-lactam antibiotic; however, the recent opportunities posted under this code involve unrelated pharmaceutical products—doxycycline hyclate, ciprofloxacin hydrochloride, and naloxone—that do not match temocillin's scope. State and local health departments and counties do source antibiotics and emergency pharmaceuticals through piggyback cooperative purchasing vehicles and competitive bidding, but the posted records do not reflect active solicitations for temocillin itself. When health jurisdictions procure pharmaceuticals at scale, they typically use established cooperative purchasing consortia such as MMCAP Infuse and award fixed-term contracts to qualified distributors on a lowest-price-responsive-responsible basis.

The two most recent records posted under this code involve Illinois Department of Public Health's completed piggyback award to Chartwell Rx LLC for antibiotic tablets (awarded August 28, 2026, under MMCAP Infuse for $2,999,999.11 over three years) and Seminole County, Florida's Invitation for Bid for naloxone and drug deactivation systems (posted June 30, 2026, with a July 26, 2023 response deadline). Neither opportunity actively solicits temocillin. The code's tagging appears to reflect broad pharmaceutical categorization rather than product-specific procurement. Business development activity under this code should wait for solicitations that explicitly name temocillin or similar narrow-spectrum antibiotics in scope; current posted activity offers no entry point for targeted pursuit.